Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type (Crohn's Disease, Ulcerative Colitis), By Drug Class, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2021 - 2028

Report Overview

The global inflammatory bowel disease treatment market size was valued at USD 19.2 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 4.8% from 2021 to 2028. The rising prevalence of Crohn’s disease and ulcerative disease across the globe is expected to drive market growth over the forecast period. Moreover, increasing adoption of biologics for the treatment and the presence of strong pipeline drugs such as upadacitinib, risankizumab, tofacitinib, ustekinumab, and others is anticipated to boost the market growth in the coming years. The impact of the COVID-19 pandemic on the market was negligible in 2020 whereas, a downfall in the diagnosis of inflammatory bowel disease has been observed in many countries due to the complete lockdown imposed in those countries.

The increasing prevalence of Crohn’s disease and ulcerative colitis is one of the key factors expected to drive the market for inflammatory bowel disease treatment. According to the Crohn’s and Colitis Foundation (CCFA), around 70,000 new cases of inflammatory bowel disease are diagnosed in the U.S. every year. As per the CCFA report of 2019, about 1.6 million people were living with Inflammatory Bowel Disease in the U.S. Moreover, according to the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA), there were around 3.4 million people in Europe living with any form of IBD in 2020. An increasing number of people are being affected by IBD thereby increasing the demand for effective treatment options.

The presence of strong pipeline products for the treatment of Inflammatory Bowel Disease (IBD) is going to drive market growth. According to the U.S. National Library of Medicine, as of October 2019, there are a total of 730 clinical trials (includes drug development, observational studies, and others) related to IBD, and out of these 268 clinical trials are being conducted in the United States only. In the drug development against the inflammatory bowel disease segment, there are 63 clinical trials in phase-1, 132 clinical trials in phase-2, and 101 clinical trials in phase-3 globally. For instance, AbbVie Inc.’s Rinvoq (upadacitinib), a JAK inhibitor, is a promising drug candidate under phase 3 clinical trial for the treatment of Crohn's disease and ulcerative colitis. Companies are engaged in the development of JAK inhibitors, anti-interleukin, S1P modulators, and other biologics to treat IBD.

Increasing approval of biosimilars such as Hyrimoz, Imraldi, Renflexis, and Inflectra is expected to increase the adoption of effective treatment due to its advantages over traditional treatment options. Other biosimilar products like Cyltezo (Boehringer Ingelheim), Hulio (Mylan N.V.), Avsola (Amgen Inc.), IXIFI (Pfizer Inc.) have received approval and are expected to be commercialized in near future. The launch of biosimilars is expected to increase the demand from emerging markets as these markets are price sensitive. Also, the increasing approval of biosimilars for pediatric Crohn’s disease will contribute to market growth globally.

Type Insights 

Crohn’s disease dominated the market for inflammatory bowel disease treatment and accounted for the largest revenue share of 61.3% in 2020. The segment is anticipated to maintain its dominance throughout the forecast period. High prevalence rate, increasing prescription rate of biologics, and high cost associated with Crohn’s disease treatment are factors driving the market for inflammatory bowel disease treatment. According to Crohn’s and Colitis Foundation, around 25% of patients with Crohn's disease in the U.S. are prescribed biologics. Moreover, the prevalence of Crohn’s disease in North America and Europe is about 319 per 100,000 population and 322 per 100,000 population respectively.

The ulcerative colitis segment is anticipated to witness significant growth over the forecast period due to the high patient base and increasing approval of biologics for the treatment of ulcerative colitis. Ulcerative colitis patients accounted for 54% of the total diagnosed inflammatory bowel disease patients in the U.S. and Europe in 2020. Moreover, the usage of biologics to treat ulcerative colitis is anticipated to increase at a significant rate in the coming years.

Drug Class Insights

The TNF inhibitors segment dominated the market for inflammatory bowel disease treatment and accounted for the largest revenue share of 47.8% in 2020. The segment is anticipated to maintain its dominance during the forecast period. The high prescription rate of TNF inhibitors such as Humira & Remicade and the effectiveness of drugs on IBD are anticipated to increase its demand over the forecast period. However, the loss of market exclusivity of Humira in the United States in 2023 is expected to negatively impact the growth of the segment in the country. In 2023, biosimilars for Humira such as Hyrimoz, Imraldi, Hadlima, and others are expected to be launched in the United States. The introduction of biosimilars is anticipated to decrease the market share of TNF inhibitors in terms of revenue.

The drug classes such as anti-integrin, aminosalicylates, and corticosteroids also have a significant share in the inflammatory bowel disease treatment market. Aminosalicylates is the first-line therapy for IBD treatment. However, JAK inhibitors are expected to grow at the fastest rate over the forecast period. The recent approval of Pfizer’s Xeljanz for the treatment of ulcerative colitis and the presence of late-phase pipeline candidates such as upadacitinib, tofacitinib, and filgotinib are expected to drive the JAK inhibitors segment growth over the forecast period.

Route of Administration Insights

The injectable segment dominated the market for inflammatory bowel disease treatment and accounted for a revenue share of more than 75.0% in 2020. The dominance of the injectable segment is owing to the high efficacy of the injectable drugs. Injectables include IL inhibitors such as Stelara (ustekinumab), TNF inhibitors such as Remicade (infliximab), Humira (adalimumab), Cimzia (certolizumab), and anti-integrin Tysabri (natalizumab), Entyvio (vedolizumab). The high prescription rate and the high cost of these drugs are major factors for the dominance of the injectables segment.

The oral route of drug administration is estimated to witness the highest growth rate over the forecast period. The growth of this segment can be attributed to the approval of JAK inhibitors for IBD treatment and the presence of strong oral pipeline products for the treatment of inflammatory bowel disease. The impending launch of JAK inhibitors and S1P modulators is expected to boost the market growth in the coming years.

Distribution Channel Insights

The hospital pharmacy segment dominated the market for inflammatory bowel disease treatment and accounted for the largest revenue share of 46.8% in 2020. The segment is anticipated to dominate the market over the forecast period. The high cost of biologics and increase in hospitalization of inflammatory bowel disease patients is driving the market growth. Retail pharmacy held the second-largest share in the IBD market and is expected to increase at a lucrative growth rate over the forecast period.

The online pharmacy segment is expected to grow at the fastest rate in the next 6 to 8 years. The growth of the online pharmacy segment can be attributed to the increase in online consultations from specialist doctors and the convenience and flexibility in online medicine purchasing. Moreover, the overall increase in internet usage and betterment in rules and regulations related to online purchasing of medicinal products are fueling the market growth.

Regional Insights

North America dominated the market for inflammatory bowel disease treatment and accounted for the largest revenue share of around 60.0% in 2020. The region is expected to experience lucrative growth over the forecast period. High treatment rates, increasing prescription of novel drugs, and better reimbursement policies in the region are factors supporting market growth in the region. Moreover, increasing research and development activities to develop effective treatment options and the presence of major pharmaceutical companies in the region are the factors expected to fuel market growth over the forecast period. For instance, according to the U.S. National Library of Medicine, as of October 2019, there is a total of 730 clinical trials related to IBD, and out of these, 268 clinical trials are being conducted in the United States only.

In Asia Pacific, the market for inflammatory bowel disease treatment is anticipated to grow at the fastest rate over the forecast period. The increasing prevalence of Crohn’s disease and ulcerative colitis in the region, increasing prescription of biosimilars, and rising novel drug approval are expected to drive the market in the coming years. According to a study published in NCBI, the prevalence of Crohn’s disease is higher in men compared to women. The highest incidence of inflammatory bowel disease is observed in East Asia including Japan, Korea, China, and others. Moreover, economic growth in the countries such as India and China is expected to propel market growth.

Key Companies & Market Share Insights

Major pharmaceutical companies are largely involved in the development of novel therapies to treat the severe condition of inflammatory bowel disease. Companies such as AbbVie Inc., Pfizer Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, and others are involved in the development of novel drugs for the treatment of IBD. Some other prominent players in the inflammatory bowel disease treatment market include:

• AbbVie Inc.

• Biogen

• Johnson & Johnson Services, Inc.

• Amgen Inc.

• UCB S.A.

• Novartis AG

• Takeda Pharmaceutical Company Limited

• Merck & Co., Inc.

• Pfizer Inc.

• Lilly

Inflammatory Bowel Disease Treatment Market Report Scope 

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the global inflammatory bowel disease treatment market report on the basis of type, drug class, route of administration, distribution channel, and region:

• Type Outlook (Revenue, USD Million, 2017 - 2028)

  • Crohn's Disease

  • Ulcerative Colitis

• Drug Class Outlook (Revenue, USD Million, 2017 - 2028)

  • Aminosalicylates

  • Corticosteroids

  • TNF inhibitors

  • IL inhibitors

  • Anti-integrin

  • JAK inhibitors

  • Others

• Route of Administration Outlook (Revenue, USD Million, 2017 - 2028)

  • Oral

  • Injectable

• Distribution Channel Outlook (Revenue, USD Million, 2017 - 2028)

  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy

• Regional Outlook (Revenue, USD Million, 2017 - 2028)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • India

    • China

    • Japan

    • Australia

    • South Korea

    • Singapore

  • Latin America

    • Argentina

    • Brazil

    • Mexico

  • Middle East & Africa

    • Saudi Arabia

    • UAE

    • South Africa